|
|
Volumn 70, Issue 23, 2013, Pages 2054-
|
|
Macitentan approved by FDA to delay progression of PAH
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
HEMOGLOBIN;
LIVER ENZYME;
MACITENTAN;
ENDOTHELIN RECEPTOR;
N (5 (4 BROMOPHENYL) 6 (2 (5 BROMOPYRIMIDIN 2 YLOXY)ETHOXY)PYRIMIDIN 4 YL) N' PROPYLAMINOSULFONAMIDE;
N-(5-(4-BROMOPHENYL)-6-(2-(5-BROMOPYRIMIDIN-2-YLOXY)ETHOXY)PYRIMIDIN-4-YL)-N'-PROPYLAMINOSULFONAMIDE;
PYRIMIDINE DERIVATIVE;
SULFONAMIDE;
BLISTER PACK;
CONTRACEPTION;
DISEASE COURSE;
DRUG APPROVAL;
DRUG CLASSIFICATION;
DRUG LABELING;
EXERCISE;
FOOD AND DRUG ADMINISTRATION;
HEMOGLOBIN BLOOD LEVEL;
HUMAN;
NOTE;
PHARMACIST;
PREGNANT WOMAN;
PULMONARY HYPERTENSION;
TABLET;
DRUG ANTAGONISM;
PATHOPHYSIOLOGY;
UNITED STATES;
DISEASE PROGRESSION;
DRUG APPROVAL;
HUMANS;
HYPERTENSION, PULMONARY;
PYRIMIDINES;
RECEPTORS, ENDOTHELIN;
SULFONAMIDES;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 84903166494
PISSN: 10792082
EISSN: 15352900
Source Type: Journal
DOI: 10.2146/news130076 Document Type: Note |
|
Times cited : (4)
|
|
References (0)
|
